Department of Pharmaceutical Sciences, University of Basel, Basel 4056, Switzerland.
Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg 69120, Germany.
Mol Pharm. 2021 May 3;18(5):2004-2014. doi: 10.1021/acs.molpharmaceut.0c01222. Epub 2021 Apr 12.
Recently, a lipopeptide derived from the hepatitis B virus (HBV) large surface protein has been developed as an HBV entry inhibitor. This lipopeptide, called MyrcludexB (MyrB), selectively binds to the sodium taurocholate cotransporting polypeptide (NTCP) on the basolateral membrane of hepatocytes. Here, the feasibility of coupling therapeutic enzymes to MyrB was investigated for the development of enzyme delivery strategies. Hepatotropic targeting shall enable enzyme prodrug therapies and detoxification procedures. Here, horseradish peroxidase (HRP) was conjugated to MyrB via maleimide chemistry, and coupling was validated by SDS-PAGE and reversed-phase HPLC. The specificity of the target recognition of HRP-MyrB could be shown in an NTCP-overexpressing liver parenchymal cell line, as demonstrated by competitive inhibition with an excess of free MyrB and displayed a strong linear dependency on the applied HRP-MyrB concentration. studies in zebrafish embryos revealed a dominating interaction of HRP-MyrB with scavenger endothelial cells vs xenografted NTCP expressing mammalian cells. In mice, radiolabeled I-HRP-MyrBy, as well as the non-NTCP targeted control HRP-peptide-construct (I-HRP-alaMyrBy) demonstrated a strong liver accumulation confirming the nonspecific interaction with scavenger cells. Still, MyrB conjugation to HRP resulted in an increased and NTCP-mediated hepatotropism, as revealed by competitive inhibition. In conclusion, the model enzyme HRP was successfully conjugated to MyrB to achieve NTCP-specific targeting with the potential for diagnostic applications. , target specificity was reduced by non-NTCP-mediated interactions. Nonetheless, tissue distribution experiments in zebrafish embryos provide mechanistic insight into underlying scavenging processes indicating partial involvement of receptors.
最近,一种源自乙型肝炎病毒(HBV)大表面蛋白的脂肽已被开发为 HBV 进入抑制剂。这种脂肽称为 MyrcludexB(MyrB),它选择性地结合到肝细胞基底外侧膜上的牛磺胆酸钠共转运多肽(NTCP)上。在这里,研究了将治疗酶偶联到 MyrB 上的可行性,以开发酶递药策略。肝靶向性可实现酶前药疗法和解毒程序。在这里,辣根过氧化物酶(HRP)通过马来酰亚胺化学与 MyrB 偶联,并通过 SDS-PAGE 和反相 HPLC 验证了偶联。HRP-MyrB 的特异性靶识别可以在过表达 NTCP 的肝实质细胞系中显示出来,这可以通过与过量游离 MyrB 的竞争抑制来证明,并且与所应用的 HRP-MyrB 浓度呈强线性依赖性。在斑马鱼胚胎中的研究表明,HRP-MyrB 与吞噬内皮细胞的强烈相互作用,而与异种移植的表达 NTCP 的哺乳动物细胞的相互作用较弱。在小鼠中,放射性标记的 I-HRP-MyrB y,以及非 NTCP 靶向的对照 HRP-肽构建体(I-HRP-alaMyrB y),都证明了强烈的肝脏积累,证实了与吞噬细胞的非特异性相互作用。尽管如此,MyrB 与 HRP 的偶联导致了增加的和 NTCP 介导的肝靶向性,这是通过竞争抑制来揭示的。总之,成功地将模型酶 HRP 偶联到 MyrB 上,以实现 NTCP 特异性靶向,并具有潜在的诊断应用。尽管如此,在斑马鱼胚胎中的组织分布实验为潜在的吞噬过程提供了机制见解,表明部分涉及 受体。